1-10 of 10
Daniel A. Vallera
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A066: Could ancestry play a role in cancer development? Insights from a risk assessment and early detection test of naturally occurring cancers in companion dogs

Ashley J Schulte, Taylor A DePauw, Ali Khammanivong, Mitzi Lewellen, Lauren Burt, Rose Dicovitsky, Amber L Winter, Kathleen M Stuebner, Andrea Chehadeh, Sara Pracht, Christopher Ober, Kari L Anderson, Esther Nell, Antonella Borgatti, Michael S Henson, Erin B Dickerson, Aaron L Sarver, Daniel A Vallera, Gary R Cutter, Jaime F Modiano
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (21_Supplement): A066.
https://doi.org/10.1158/1557-3265.LIQBIOP24-A066
Published: 13 November 2024
View article titled, Abstract A066: Could ancestry play a role in cancer development? Insights from a risk assessment and early detection test of naturally occurring cancers in companion dogs
Journal Articles

ImmunoPET, [64Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model

Sargur Madabushi Srideshikan, Jamison Brooks, Darren Zuro, Bijender Kumar, James Sanchez, Liliana Echavarria Parra, Marvin Orellana, Paresh Vishwasrao, Indu Nair, Junie Chea, Kofi Poku, Nicole Bowles, Aaron Miller, Todd Ebner, Justin Molnar, Joseph Rosenthal, Daniel A. Vallera, Jeffrey Y.C. Wong, Anthony S. Stein, David Colcher, John E. Shively, Paul J. Yazaki, Susanta K. Hui
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7463–7474.
https://doi.org/10.1158/1078-0432.CCR-19-1106
Published: 13 December 2019
View article titled, ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model
Open the PDF for ImmunoPET, [<sup>64</sup>Cu]Cu-DOTA-Anti-CD33 PET-CT, Imaging of an AML Xenograft Model in another window
Includes: Supplementary data
Journal Articles

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

Daniel A. Vallera, Martin Felices, Ron McElmurry, Valarie McCullar, Xianzheng Zhou, Joerg Uwe Schmohl, Bin Zhang, Alexander J. Lenvik, Angela Panoskaltsis-Mortari, Michael R. Verneris, Jakub Tolar, Sarah Cooley, Daniel J. Weisdorf, Bruce R. Blazar, Jeffrey S. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (14): 3440–3450.
https://doi.org/10.1158/1078-0432.CCR-15-2710
Published: 14 July 2016
View article titled, IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33<sup>+</sup> Targets While Also Inducing Persistence, <em>In Vivo</em> Expansion, and Enhanced Function
Open the PDF for IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33<sup>+</sup> Targets While Also Inducing Persistence, <em>In Vivo</em> Expansion, and Enhanced Function in another window
Includes: Supplementary data
Journal Articles

Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies

Veronika Bachanova, Arthur E. Frankel, Qing Cao, Dixie Lewis, Bartosz Grzywacz, Michael R. Verneris, Celalettin Ustun, Aleksandr Lazaryan, Brian McClune, Erica D. Warlick, Hagop Kantarjian, Daniel J. Weisdorf, Jeffrey S. Miller, Daniel A. Vallera
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (6): 1267–1272.
https://doi.org/10.1158/1078-0432.CCR-14-2877
Published: 12 March 2015
View article titled, Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies
Open the PDF for Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies in another window
Journal Articles

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition

Andres Wiernik, Bree Foley, Bin Zhang, Michael R. Verneris, Erica Warlick, Michelle K. Gleason, Julie A. Ross, Xianghua Luo, Daniel J. Weisdorf, Bruce Walcheck, Daniel A. Vallera, Jeffrey S. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (14): 3844–3855.
https://doi.org/10.1158/1078-0432.CCR-13-0505
Published: 15 July 2013
View article titled, Targeting Natural Killer Cells to Acute Myeloid Leukemia <em>In Vitro</em> with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition
Open the PDF for Targeting Natural Killer Cells to Acute Myeloid Leukemia <em>In Vitro</em> with a CD16 × 33 Bispecific Killer Cell Engager and ADAM17 Inhibition in another window
Journal Articles

A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma

Seunguk Oh, Brad J. Stish, Deepali Sachdev, Hua Chen, Arkadiusz Z. Dudek, Daniel A. Vallera
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (19): 6137–6147.
https://doi.org/10.1158/1078-0432.CCR-09-0696
Published: 30 September 2009
View article titled, A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma
Open the PDF for A Novel Reduced Immunogenicity Bispecific Targeted Toxin Simultaneously Recognizing Human Epidermal Growth Factor and Interleukin-4 Receptors in a Mouse Model of Metastatic Breast Carcinoma in another window
Journal Articles

A Bispecific Recombinant Cytotoxin (DTEGF13) Targeting Human Interleukin-13 and Epidermal Growth Factor Receptors in a Mouse Xenograft Model of Prostate Cancer

Brad J. Stish, Hua Chen, Yanqun Shu, Angela Panoskaltsis-Mortari, Daniel A. Vallera
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (21): 6486–6493.
https://doi.org/10.1158/1078-0432.CCR-07-0938
Published: 01 November 2007
View article titled, A Bispecific Recombinant Cytotoxin (DTEGF13) Targeting Human Interleukin-13 and Epidermal Growth Factor Receptors in a Mouse Xenograft Model of Prostate Cancer
Open the PDF for A Bispecific Recombinant Cytotoxin (DTEGF13) Targeting Human Interleukin-13 and Epidermal Growth Factor Receptors in a Mouse Xenograft Model of Prostate Cancer in another window
Journal Articles

Increasing Anticarcinoma Activity of an Anti-erbB2 Recombinant Immunotoxin by the Addition of an Anti-EpCAM sFv

Brad J. Stish, Hua Chen, Yanqun Shu, Angela Panoskaltsis-Mortari, Daniel A. Vallera
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (10): 3058–3067.
https://doi.org/10.1158/1078-0432.CCR-06-2454
Published: 15 May 2007
View article titled, Increasing Anticarcinoma Activity of an Anti-erbB2 Recombinant Immunotoxin by the Addition of an Anti-EpCAM sFv
Open the PDF for Increasing Anticarcinoma Activity of an Anti-erbB2 Recombinant Immunotoxin by the Addition of an Anti-EpCAM sFv in another window
Journal Articles

Radioimmunotherapy of CD22-Expressing Daudi Tumors in Nude Mice with a 90Y-Labeled Anti-CD22 Monoclonal Antibody

Daniel A. Vallera, Martin W. Brechbiel, Linda J. Burns, Angela Panoskaltsis-Mortari, Katie E. Dusenbery, Dennis R. Clohisy, Ellen S. Vitetta
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7920–7928.
https://doi.org/10.1158/1078-0432.CCR-05-0725
Published: 08 November 2005
View article titled, Radioimmunotherapy of CD22-Expressing Daudi Tumors in Nude Mice with a <sup>90</sup>Y-Labeled Anti-CD22 Monoclonal Antibody
Open the PDF for Radioimmunotherapy of CD22-Expressing Daudi Tumors in Nude Mice with a <sup>90</sup>Y-Labeled Anti-CD22 Monoclonal Antibody in another window
Journal Articles

A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma

Daniel A. Vallera, Deborah A. Todhunter, David W. Kuroki, Yanqun Shu, Andy Sicheneder, Hua Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (10): 3879–3888.
https://doi.org/10.1158/1078-0432.CCR-04-2290
Published: 16 May 2005
View article titled, A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma
Open the PDF for A Bispecific Recombinant Immunotoxin, DT2219, Targeting Human CD19 and CD22 Receptors in a Mouse Xenograft Model of B-Cell Leukemia/Lymphoma in another window